scholarly journals Excision Repair Cross-Complementation Group 1 (ERCC1): A Prognostic and Predictive Biomarker in Patients with Colorectal Cancer Receiving Adjuvant Oxaliplatin Based Chemotherapy

2016 ◽  
Vol 07 (09) ◽  
pp. 622-634 ◽  
Author(s):  
Adel Gabr ◽  
T. M. Elsaba ◽  
Khalid Razek ◽  
Shaima Tamam ◽  
Haisam Atta
Keyword(s):  
Colorectal Cancer ◽  
Excision Repair ◽  
Predictive Biomarker ◽  
Complementation Group ◽  
Group 1

scholarly journals Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy

2016 ◽  
Vol 129 (5) ◽  
pp. 586-593 ◽  
Author(s):  
Mu-Xing Li ◽  
Xin-Yu Bi ◽  
Hong Zhao ◽  
Zhen Huang ◽  
Yue Han ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Biomarker ◽  
Excision Repair ◽  
Complementation Group ◽  
Group 1

A Review of Excision Repair Cross-complementation Group 1 in Colorectal Cancer

2011 ◽  
Vol 10 (3) ◽  
pp. 157-164 ◽  
Author(s):  
Pierre Bohanes ◽  
Melissa J. LaBonte ◽  
Heinz-Josef Lenz
Keyword(s):  
Colorectal Cancer ◽  
Excision Repair ◽  
Complementation Group ◽  
Group 1

Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer

2008 ◽  
Vol 18 (5) ◽  
pp. 1007-1012 ◽  
Author(s):  
K. Lin ◽  
D. Ye ◽  
X. Xie
Keyword(s):  
Ovarian Cancer ◽  
Protein Expression ◽  
Clear Cell ◽  
Excision Repair ◽  
Cell Cancer ◽  
Complementation Group ◽  
Serous Ovarian Cancer ◽  
Expression Levels ◽  
Platinum Based Chemotherapy ◽  
Group 1

This study was undertaken to examine whether there is an association between excision repair cross-complementation group 1 (ERCC1) and xeroderma pigmentosum D (XPD) protein expression levels and response to platinum-based chemotherapy in epithelial ovarian cancer (EOC). The study cohort consisted of 91 consecutive patients suffering from stage III or IV disease of primary EOC from 1999 to 2004 at the Women's Hospital, School of Medicine, Zhejiang University. There were 36 sensitive cases of serous ovarian cancer, 27 resistant cases of serous ovarian cancer, 15 cases of clear cell cancer, and 13 cases with serous ovarian cancer receiving neoadjuvant chemotherapy. The ovarian tissue microsections were stained by standard immunohistochemical techniques to show ERCC1 and XPD protein expression levels. In resistance group of serous ovarian cancer, ERCC1 and XPD protein expression levels were significantly higher than those of sensitivity group, and after receiving neoadjuvant chemotherapy, they showed 23% and 32% higher than before. Meanwhile, their levels of clear cell cancer group were significantly higher than serous ovarian cancer group's. Upregulation of ERCC1 and XPD protein expression was associated with resistance process to platinum-based chemotherapy in advanced EOC. This study provided evidence that differences of nucleotide excision repair–related genes expression may have an effect on the observed differences in clinical behavior of EOC

scholarly journals P-0173 Thymidilate Synthase (TS) and Excision Repair Complementation Group 1 (ERCC1) Status And Clinicopathologic Factors in Gastro-Intestinal Cancer

2012 ◽  
Vol 23 ◽  
pp. iv80
Author(s):  
Ali Motlagh ◽  
Farnaz Hosseini Kamal ◽  
Seyed Ahmad Aleyasin ◽  
Payam Azadeh ◽  
Christer Larsson ◽  
...  
Keyword(s):  
Excision Repair ◽  
Complementation Group ◽  
Intestinal Cancer ◽  
Clinicopathologic Factors ◽  
Thymidilate Synthase ◽  
Group 1
Sign in / Sign up

Export Citation Format

Share Document